SVC
VC Fund
Zürich, Switzerland
SVC is a VC fund in Zürich focused on Medical and Information Technology. SVC - Ltd. for Risk Capital for SMEs provides Swiss SMEs and start-up businesses with venture capital of up to CHF 100 million. Innovative companies in various development phases are supplied with venture capital in the form of additional equity capital or as loans with profit participation. The focus is on the consolidation of Switzerland as acenter of employment and the creation or preservation of jobs. SVC - Ltd. for Risk Capital for SMEs is active throughout Switzerland.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries SVC invests in
Stages SVC invests in
Countries SVC invests in
Round sizes
Round size
- Seed
- $291k–$3M
- Series A
- $2.9M–$6.2M
- Series B
- $30M–$41M
Investment Focus
Industry
- Medical 3 (30%)
- Information Technology 3 (30%)
- Consulting 2 (20%)
- Health Care 2 (20%)
- Biotechnology 2 (20%)
Stage
- Seed 3 (30%)
- Series A 3 (30%)
- Series B 2 (20%)
- Pre-Seed 1 (10%)
- Funding Round 1 (10%)
Country
- Switzerland 5 (50%)
- Saudi Arabia 2 (20%)
- Germany 1 (10%)
- Vietnam 1 (10%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Noon Academy
|
Noon (Noon Academy previously) is a social learning platform making learning a more joyful, collaborative, and innovative experience. We believe technology and great people are what make Noon Academy so successful and a unique platform for social learning. Loved by 10+ million students across 8 countries, we’re a diverse team of people rooted indifferent backgrounds but sharing the same vision and passion. Our goals is to impact 50 million students by 2023. | $40.8M / Series B / Nov 02, 2023 | |
THEMAR
|
THEMAR is a sharia-compliant peer-to-peer purchase financing network. They connect small and microbusiness purchasers to investors through their online funding platform. | Pre-Seed / Apr 01, 2022 | |
Waggle
|
Waggle enables retail investors to participate in primary market investments and provides additional support for innovations. | $3M / Seed / Sep 22, 2021 | |
Spores Network
|
Spores Network is a GameFi and Metaverse publisher that focuses on enabling Web3 adventures with entertainment IP and corporate brands. | $2.3M / Seed / Jul 16, 2021 | |
Nezasa
|
Nezasa’s travel booking solution empowers travel brands globally to combine all planning and booking related actions into one seamless end-to-end experience.Our tools, enable to plan and book any type of multi-product or multi-stop itinerary.TripBuilder Hyper-personalised packaging Real-time planning and booking of personalised itinerariesPowerful, easy to use and very interactive Deep integration possibilities into existing fulfilment landscapes Enterprise-grade, proven with large TO customersTripBooster Hyper-personalised In-Destination Upselling The extension of TripBuilder’s power throughout the entire travel lifecycle The perfect travel companion Seamless purchasing of perfectly fitting additional products Smart upselling recommendation, available in both a push and pull mode | $2.9M / Series A / Dec 20, 2018 | |
Luciole Medical
|
Luciole Medical is a Swiss medical technology company developing brain oxygenation monitoring systems. | $6.2M / Series A / Sep 17, 2018 | |
Ava
|
Ava makes it easy to gain a profound and accurate understanding of your cycle and health—empowering you to make informed choices for your life. Because we believe every woman deserves greater control over her wellbeing, and the tools to maximize her physical and emotional potential. | $30M / Series B / May 30, 2018 | |
Scantrust
|
Scantrust is a connected goods and packaging platform for companies that depend on selling physical products in a connected world. Scantrust protects brands, establishes supply chain awareness, and offers innovative consumer engagement options. We unlock growth potential in the goods companies sell. Learn more or request a demonstration atwww.scantrust.com | $4.2M / Series A / Nov 14, 2017 | |
Eulitha
|
EULITHA was founded in 2006 in the canton Aargau of Switzerland. Its founders have led the development of Extreme Ultraviolet Interference Technology at the Paul Scherrer Institute. Having entered the market with products based on its EUV technology, Eulitha has expanded its range of products with the addition of state-of-the-art electron beamlithography technology to its capabilities. In 2010, Eulitha announced the breakthrough PHABLE™ technology, which greatly simplifies production of periodic nanostructures over wafer scale areas. The company has a global customer base of researchers from industrial and academic laboratories. Backed by private Swiss equity Eulitha serves its growing number of customers from two locations in Kirchdorf and the Paul Scherrer Institute. | $291K / Seed / Apr 05, 2012 | |
Vimecon
|
Vimecon develops and produces laser catheters for the treatment of heart diseases with a focus on atrial fibrillation. It also manufactures products for the medical technology and biotechnology; and offers microscopically small catheters, as well as micro materials handling techniques for exact measurement and dosage. Moreover, Vimecon advisesvarious customers from the scholar and industrial research and development. Kai U. Markus founded it in 2005, with its headquarters in Herzogenrath in Germany. | Jun 20, 2011 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does SVC invest in?
SVC invests primarily in Medical, Information Technology and Consulting startups, most often at Seed and Series A stage. Most of the 10 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is SVC's check size?
SVC typically joins rounds of $291k–$3M at Seed, $2.9M–$6.2M at Series A and $30M–$41M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds SVC participates in.
When did SVC last invest?
The most recent investment recorded for SVC closed in Nov 2023. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
